
Opinion|Videos|April 22, 2025
Advancing Retinal Disease Treatment – The Next Generation of Anti-VEGF Therapies
Listen
0:00 / 0:00
Ehsan Rahimy, MD; David G. Miller, MD, and Jordana Fein, MD, discusses how 8 milligram aflibercept and faricimab, newer anti-VEGF therapies for retinal diseases, offer improved durability with comparable safety profiles to existing treatments, allowing less frequent injections while maintaining equivalent vision outcomes.
Advertisement
Episodes in this series

Timecodes:
1:25- Rationale for high dose aflibercept
5:00- PULSAR trial for AMD
12:00- PHOTON trial for DME
16:21- Changing practice patterns
22:29- Faricimab and role of ang-2 inhibition
28:30 Impact of new therapies
Advertisement
Related to this article

In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next.

At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics.

Pooled, blinded week 12 data from the phase 2 RENEW trial showed FVC improvement in 8 of 24 patients with IPF and no treatment-related serious AEs.

Ankeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, review OPTIMAL-DIABETES, SYNCHRONIZE-CVOT, and ATTAIN-OSA data from AHA 2026.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss tubeless Mobi's FDA clearance, CVS Caremark's CGM formulary shift, and a transmitter-free implant.

Aficamten's label now includes MAPLE-HCM data, in which aficamten monotherapy improved peak VO2 by 2.3 mL/kg/min more than metoprolol at 24 weeks.
Advertisement
Advertisement
Trending on HCPLive
1
Upadacitinib Response Within Days in Crohn’s Disease, With Raja Atreya, MD
2
Stepwise Chronic Spontaneous Urticaria Management, With Timothy Craig, DO
3
Ultra-Processed Food Intake Increases Risk of HF in All Phenotypes
4
Top Videos From 2026 Dermatology Meetings: 12 Expert Interviews to Watch
5



